The German laboratory BioNTech has told Euronews it plans to submit an application in the EU for authorisation for the use of its COVID-19 vaccine with Pfizer in children aged 12 to 15.
The pharmaceutical company said it could have collected data for children younger than this age bracket by September.
BioNTech/Pfizer said in March that its vaccine has proven to be 100% effective in youngsters aged 12 to 15.
Phase 3 trials involving 2,260 children in the United States “demonstrated 100% efficacy and robust antibody responses,” the German-American company duo said in a statement.
They said they hope to begin vaccinating this age group before the next school year, and will seek authorisation from the US Food and Drug Administration and the European Medicines Agency to expand the use of the vaccine.
The UK government yesterday announced it has purchased a further 60 million doses of BioNTech/Pfizer’s vaccine to support its planned booster programme from autumn.
It comes after the EU announced earlier this month it was focussing on mRNA vaccines for its rollout and is in talks to buy a further 1.8 billion doses of the jab.
“We need to focus on technologies that have proven their worth: mRNA vaccines are a clear case in point,” European Commission President Ursula von der Leyen said in mid-April.
The head of the BioNTech laboratory said on Wednesday that he is “confident” their COVID vaccine is effective against the Indian variant.
The COVID-19 variant is believed to be behind a devastating surge of infections and deaths in India and has been detected in 17 countries worldwide including multiple European nations.
The B.1.617 variant has multiple sub-lineages which slightly differ by their characteristic mutations but one of the main ones, called L452R, has been associated with increased transmissibility and lower resistance to treatment including vaccination, the WHO noted.
While children of all ages are susceptible to and can transmit SARS-CoV-2, surveillance data from the European Centre for Disease Prevention and Control (ECDC) showed children between 1-18 years of age have lower rates of hospitalisation, severe hospitalisation and death from COVID than all other age groups.
Younger children also appear to be less susceptible to infection, and when infected, less often lead to onward transmission than older children and adults, according to the agency.
But experts insist that to make the world safe from COVID-19, everyone must be vaccinated, including children.
“Serious illness is rare, but well-described; this includes the inflammatory and potentially deadly condition Multisystem Inflammatory Syndrome in Children (MIS-C). Approximately 1 in 3,500 child cases result in death, compared with a figure of 1 in 60 for adults,” the vaccine alliance Gavi said.
“To get back to normality, we also need vaccinated adults, ongoing safety measures, safe re-opening of schools, access to all recommended vaccines – and importantly, a rigorous pathway to identifying truly safe COVID-19 vaccines for children, Anita Shet, Director of Child Health, International Vaccine Access Center said in March.